All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
FDA approves motixafortide plus filgrastim for hematopoietic stem cell mobilization
Bookmark this article
On September 11, 2023, the U.S. Food and Drug Administration granted approval to motixafortide plus filgrastim for use in mobilization of hematopoietic stem cells for collection and subsequent autologous transplant.1
Motixafortide, a cyclic-peptide CXCR4 inhibitor, in combination with filgrastim, a type of granulocyte colony-stimulating factor, has been approved based on data from the phase III GENESIS trial (NCT03246529). The trial design and interim data from GENESIS have previously been reported by the Multiple Myeloma Hub here.
GENESIS - latest data1
The latest analysis from GENESIS includes 92 patients treated with 1.25 mg/kg motixafortide plus filgrastim subcutaneously, and 42 patients treated with a placebo plus filgrastim.
- Patients who reached the stem cell collection goal of ≥6 × 106 CD34+ cells/kg within two apheresis sessions:
- motixafortide plus filgrastim cohort, 67.5%
- placebo plus filgrastim cohort, 9.5%
- Incidence of serious adverse events:
- motixafortide plus filgrastim cohort, 5.4%
- The most common adverse events were injection site reactions, pruritus, flushing, and back pain.
- BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma. https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-fda-approval-aphexdatm-motixafortide. Published September 11, 2023. Accessed September 13, 2023.
More about...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox